Holen Sie sich die Stockscreener-App
208.95
2.31%
4.71
Handel nachbörslich:
208.95
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$204.24
Offen:
$204.85
24-Stunden-Volumen:
189.22K
Relative Volume:
0.91
Marktkapitalisierung:
$4.11B
Einnahmen:
$152.42M
Nettoeinkommen (Verlust:
$45.24M
KGV:
83.25
EPS:
2.51
Netto-Cashflow:
$6.97M
1W Leistung:
+9.17%
1M Leistung:
+5.35%
6M Leistung:
+24.57%
1J Leistung:
+81.29%
1-Tages-Spanne:
$198.37
$209.23
1-Wochen-Bereich:
$178.72
$209.23
52-Wochen-Spanne:
$93.58
$212.49
Ligand Pharmaceuticals Inc Stock (LGND) Company Profile
Firmenname
Ligand Pharmaceuticals Inc
Sektor
Branche
Telefon
858-550-7500
Adresse
3911 SORRENTO VALLEY BLVD, SAN DIEGO, CA
Compare LGND vs VRTX, REGN, ARGX, ALNY, ONC
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
LGND
Ligand Pharmaceuticals Inc
|
208.95 | 4.02B | 152.42M | 45.24M | 6.97M | 2.51 |
|
VRTX
Vertex Pharmaceuticals Inc
|
477.89 | 120.48B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
787.50 | 81.05B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
749.56 | 46.33B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
327.30 | 42.26B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
299.02 | 32.87B | 5.36B | 287.73M | 924.18M | 2.5229 |
Ligand Pharmaceuticals Inc Stock (LGND) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-12-09 | Eingeleitet | Citigroup | Buy |
| 2025-04-10 | Eingeleitet | Stifel | Buy |
| 2024-10-03 | Eingeleitet | Oppenheimer | Outperform |
| 2024-07-30 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2021-04-14 | Fortgesetzt | Stephens | Overweight |
| 2021-02-04 | Bestätigt | H.C. Wainwright | Buy |
| 2020-10-06 | Eingeleitet | Barclays | Overweight |
| 2020-03-24 | Herabstufung | Argus | Buy → Hold |
| 2020-03-10 | Eingeleitet | Guggenheim | Neutral |
| 2020-02-06 | Eingeleitet | The Benchmark Company | Buy |
| 2019-09-19 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2019-06-11 | Eingeleitet | Barclays | Equal Weight |
| 2019-05-03 | Bestätigt | H.C. Wainwright | Buy |
| 2019-03-06 | Bestätigt | H.C. Wainwright | Buy |
| 2018-10-29 | Hochstufung | ROTH Capital | Neutral → Buy |
| 2018-10-02 | Bestätigt | H.C. Wainwright | Buy |
| 2018-09-11 | Bestätigt | Argus | Buy |
| 2018-08-17 | Eingeleitet | Goldman | Neutral |
| 2018-08-08 | Herabstufung | ROTH Capital | Buy → Neutral |
| 2018-06-21 | Eingeleitet | Argus | Buy |
| 2017-12-27 | Bestätigt | H.C. Wainwright | Buy |
| 2017-09-05 | Fortgesetzt | H.C. Wainwright | Buy |
| 2016-10-05 | Bestätigt | H.C. Wainwright | Buy |
| 2016-08-05 | Herabstufung | Deutsche Bank | Hold → Sell |
| 2016-03-11 | Eingeleitet | Sidoti | Buy |
| 2016-03-03 | Eingeleitet | H.C. Wainwright | Buy |
Alle ansehen
Ligand Pharmaceuticals Inc Aktie (LGND) Neueste Nachrichten
Ligand Pharmaceuticals (LGND) Is Up 8.1% After Swinging to Profit and Filing New Equity ShelfWhat's Changed - simplywall.st
[144] LIGAND PHARMACEUTICALS INC SEC Filing - Stock Titan
Ligand plans three March investor appearances in Miami, Dana Point, NYC - Stock Titan
Ligand Pharma (LGND) Earnings Call Transcript - AOL.com
Ligand Pharmaceuticals (LGND): Investor Outlook With 20.74% Potential Upside - DirectorsTalk Interviews
LGND: 2025 Results & Focus on Qtorin - Yahoo Finance
Ligand Pharmaceuticals (LGND) Is Up 7.8% After Swing to Profit and New ATM Offering Filed – Has The Bull Case Changed? - Yahoo Finance
Expert Outlook: Ligand Pharmaceuticals Through The Eyes Of 5 Analysts - Sahm
Viridian Therapeutics Stock Up 75%, but One Fund Just Sold Off Its $69 Million Stake - AOL.com
LGND Should I Buy - Intellectia AI
Decoding Ligand Pharmaceuticals Inc (LGND): A Strategic SWOT Ins - GuruFocus
Ligand Pharmaceuticals Files For Mixed Shelf Offering - TradingView
Ligand Pharmaceuticals (NASDAQ: LGND) files S-3 for $100M ATM offering with Leerink - Stock Titan
LIGAND PHARMACEUTICALS INC SEC 10-K Report - TradingView
Oppenheimer Raises Price Target for LGND, Maintains Outperform R - GuruFocus
Oppenheimer Adjusts Price Target on Ligand Pharmaceuticals to $277 From $275, Maintains Outperform Rating - marketscreener.com
Vanguard Group Inc. Has $367.79 Million Stake in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Oppenheimer raises Ligand Pharma stock price target on royalty outlook By Investing.com - Investing.com Canada
Ligand Pharmaceuticals (NASDAQ:LGND) Announces Quarterly Earnings Results, Beats Expectations By $0.56 EPS - MarketBeat
Ligand Pharmaceuticals Incorporated (LGND) Q4 2025 Earnings Call Transcript Summary - 富途牛牛
Ligand Pharmaceuticals Q4 Earnings Call Highlights - MarketBeat
Ligand Pharmaceuticals Inc (LGND) Q4 2025 Earnings Call Highligh - GuruFocus
Ligand Pharmaceuticals Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Ligand Pharmaceuticals Incorporated Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2025 - marketscreener.com
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
Ligand Pharmaceuticals Incorporated Reiterates Earnings Guidance for the Year 2026 - marketscreener.com
Ligand Pharmaceuticals Q4 Adjusted Net Income, Revenue Rise; Reaffirms 2026 Guidance - marketscreener.com
Ligand Pharmaceuticals (NASDAQ:LGND) Updates FY 2026 Earnings Guidance - MarketBeat
Ligand (LGND) Surpasses Q4 Revenue Expectations with Robust Perf - GuruFocus
(LGND) Ligand Pharmaceuticals Expects 2026 Total Revenue Range $245M-$285M, vs. FactSet Est of $265.7M - marketscreener.com
(LGND) Ligand Pharmaceuticals Expects 2026 Adjusted EPS Range $8.00-$9.00, vs. FactSet Est of $8.42 - marketscreener.com
Ligand: Q4 Financial Results Overview - Bitget
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Reports Q4 Revenue $59.7M, vs. FactSet Est of $55.6M - marketscreener.com
Earnings Flash (LGND) Ligand Pharmaceuticals Incorporated Posts Q4 Adjusted EPS $2.02 per Share, vs. FactSet Est of $1.50 - marketscreener.com
Ligand Pharmaceuticals Reports Strong Q4 and Full Year 2025 Financial Results - TradingView
Ligand Reports Fourth Quarter and Full Year 2025 Financial Results - The Manila Times
BRIEF-Ligand Pharmaceuticals Q4 EPS USD 2.12 - TradingView
Pharma group Ligand swings from loss to $124M profit as royalties jump - Stock Titan
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNZZ - TradingView
H.C. Wainwright Maintained Buy on Ligand (LGND) Feb 24, 2026 - Meyka
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 at HC Wainwright - Defense World
Net current asset value per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Operating cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Free cash flow per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Total debt per share of Ligand Pharmaceuticals Incorporated – OTC:LGNXZ - TradingView
Ligand Pharmaceuticals (NASDAQ:LGND) Price Target Raised to $239.00 - MarketBeat
LGND Analyst Rating Update: HC Wainwright & Co. Raises Price Tar - GuruFocus
Ligand Pharmaceuticals IncorporatedEquity Right (LGNXZ) Price Target Increased by 68.71% to 0.00 - Nasdaq
State of New Jersey Common Pension Fund D Takes $2.40 Million Position in Ligand Pharmaceuticals Incorporated $LGND - MarketBeat
Ligand Pharmaceuticals Incorporated $LGND Shares Bought by Envestnet Asset Management Inc. - Defense World
Volatility Watch: Is Ligand Pharmaceuticals Incorporated being accumulated by smart moneyPortfolio Gains Summary & Risk Adjusted Buy and Sell Alerts - baoquankhu1.vn
Finanzdaten der Ligand Pharmaceuticals Inc-Aktie (LGND)
Umsatz
Nettogewinn
Free Cashflow
ENV
0.11%
6.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):